The Valley Desk

NCT02071862 · Interventional trial

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Overall registry status Completed

Phase 1

Conditions Fumarate Hydratase (FH)-Deficient Tumors, Mesothelioma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Solid Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Triple-Negative Breast Cancer, Tumors Harboring Amplifications in the cMyc Gene, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov